REVIEWAn update on biomarkers of heart failure in hypertensive patientsGluba, Annaa; Bielecka, Agatab; Mikhailidis, Dimitri P.c; Wong, Nathan D.d; Franklin, Stanley S.d; Rysz, Jaceka; Banach, MaciejbAuthor Information aDepartment of Nephrology, Hypertension and Family Medicine bDepartment of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland cDepartment of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), London, UK dDepartment of Medicine, University of CA, Irvine, California, USA Correspondence to Maciej Banach, MD, PhD, FAHA, FESC; FASA, FRSPH, Head, Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Poland. Zeromskiego 113; 90–549 Lodz, Poland. Tel: +48 42 639 37 71; fax: +48 42 639 37 82; e-mail: [email protected] Abbreviations: BNP, B-type natriuretic peptide; PICP, carboxy-terminal propeptide of procollagen type I; CT-1, cardiotrophin-1; CV, cardiovascular; CHF, chronic heart failure; CAD, coronary artery disease; CRP, C-reactive protein; CysC, cystatin C; GFR, glomerular filtration rate; HF, heart failure; IL, interleukin; LV, left ventricular; LDL-C, low density lipoprotein cholesterol; MMPs, metalloproteinases; MCP-1, monocyte chemoattractant protein 1; MPO, myeloperoxidase; NO, nitric oxide; PIIINP, N-terminal propeptide of type III procollagen; RAA, renin-angiotensin-aldosterone; SUA, serum uric acid; sICAM-1, soluble intercellular adhesion molecule-1; SHR, spontaneously hypertensive rats; TIMP-1, tissue inhibitor of metalloproteinase-1; TGF, transforming growth factor; TNF, tumor necrosis factor-α CITP, type I collagen telopeptide; XO, xanthine oxidase Received 25 December, 2011 Revised 14 April, 2012 Accepted 4 June, 2012 Journal of Hypertension: September 2012 - Volume 30 - Issue 9 - p 1681-1689 doi: 10.1097/HJH.0b013e3283569a9c Buy Erratum Metrics Abstract Biomarkers should have high sensitivity, specificity, reproducibility, be cost-effective, and provide incremental predictive or diagnostic utility over standard risk factors or tests. Despite numerous studies investigating biomarkers in heart failure (HF), there are only a few that predict HF in hypertensive patients. This article summarizes data from numerous studies concerning possible biomarkers of HF in hypertensive patients such as: serum uric acid (SUA), interleukins, monocyte chemoattractant protein one (MCP-1), cardiotrophin-1 (CT-1), carboxy-terminal propeptide of procollagen type I (PICP), type I collagen telopeptide (CITP) and N-terminal propeptide of type III procollagen (PIIINP), metalloproteinases (MMPs), B-type natriuretic peptide (BNP) and its derivatives, glycoprotein CA125 and cystatin C. Early detection of patients of increased risk of hypertensive heart disease may result in early implementation of effective preventive strategies. Therefore, there is need to identify newer biomarkers, if they can improve risk prediction, identifying patients, in which earlier or more aggressive intervention will improve clinical outcomes. Erratum The name of an author is spelt incorrectly for article, ‘An update on biomarkers of heart failure in hypertensive patients.’ by Gluba A, et al . which appeared on pp. 1681–1689 of Journal of Hypertension, Volume 30, Issue 9. The author name which has been spelt as Agata Bielecka should instead be spelt as Agata Bielecka-Dabrowa. Journal of Hypertension. 31(4):844, April 2013. © 2012 Lippincott Williams & Wilkins, Inc.